Browse > Article
http://dx.doi.org/10.5292/jkbjts.2010.16.1.8

The Effect of Platelet-Rich Plasma on Allograft Transplantation after Curettage in Benign Bone Tumor  

Kim, Jae-Do (Department of Orthopaedic Surgery, Kosin University Gospel Hospital)
Kim, Ji-Youn (Department of Orthopaedic Surgery, Kosin University Gospel Hospital)
Jang, Su-Jin (Department of Orthopaedic Surgery, Kosin University Gospel Hospital)
Chung, So-Hak (Department of Orthopaedic Surgery, Kosin University Gospel Hospital)
Jung, Gu-Hee (Department of Orthopaedic Surgery, Kosin University Gospel Hospital)
Publication Information
The Journal of the Korean bone and joint tumor society / v.16, no.1, 2010 , pp. 8-13 More about this Journal
Abstract
Purpose: This study was performed to evaluate the effi ciency of Platelet-rich plasma (PRP) for acceleration of bone healing process on allograft transplantation after curettage in benign bone tumor. Materials and Methods: From December 2007 to February 2009, twenty-one patients who had benign bone tumor and underwent allograft transplantation after curettage were evaluated. Mean follow-up period was 14.6 months (range, 12-26 months). We compared with 13 cases of PRP group and 8 cases of non-PRP group in terms of size of lesion, bone resorption, amount of applied PRP and complications. The mean age at surgery was 23.6 years (range, 4-73 years). The most common diagnosis was simple bone cyst (7) followed by enchondroma (4), giant cell tumor (3), undifferentiated benign bone tumor (3) and so on. Results: The mean size of lesion was 33.5 $cm^3$ (range, 2.3-181.9 $cm^3$) (29.4 $cm^3$ in PRP group and 40.2 $cm^3$ in non-PRP group). The mean volume of injected PRP was 7.4 cc (range, 3-12 cc). Bone union started at 3.0 months (range, 1.5-5.8 months) in PRP group and 5.3 months (range, 4-8 months) in non-PRP group. Three cases for each group were excluded due to recurrence and pathologic fracture. One patient had febrile episode 3 weeks later after surgery which subsided with antibiotics. Conclusion: The PRP could accelerate bone union in allograft transplantation after curettage of benign bone tumor. Furthermore, we expect that PRP can accelerate bone union in fracture or non-union.
Keywords
benign bone tumor; allograft transplantation; platelet-rich plasma (PRP);
Citations & Related Records
연도 인용수 순위
  • Reference
1 Veillette CJ, McKe MD. Growth factors - BMPs, DBMs, and buff y coat products: are there any proven diff erences amongst them? Injury. 2007;38 Suppl 1:38-48.
2 Pietrzak WS, Eppley BL. Platelet rich plasma: biology and new technology. J Craniofac Surg. 2005;16:1043-54.   DOI   ScienceOn
3 Marx RE. Platelet-rich plasma: evidence to support its use. Maxillofac Surg. 2004;62:489-96.
4 Wilde AH, Schickendantz MS, Stulberg BN, Go RT. Th e incorporation of tibial allograft s in total knee arthroplasty. J Bone Joint Surg. 1990;72:815-24.   DOI
5 Stevenson S, Horowitz M. The response to bone allografts. J Bone Joint Surg. 1992;74:939-50.   DOI
6 Bouxsein ML, Turek TJ, Blake Ca, et al. Recombinant hu man bone morphogenetic protein-2 accelerates healing in a rab bit ulnar osteotomy model. J Bone Joint Surg. 2001;83:219-30.   DOI
7 Yeh LC, Unda R, Lee JC. Osteogenic protein-1 differentially regulates the mRNA expression of bone morphogenetic proteins and their receptors in primary cultures of osteoblasts. J Cell Physiol. 2000;185:87-97.   DOI   ScienceOn
8 Marx RE, Carlson ER, Eichstaedt RM, Schimmele SR, Strauss JE, Georgeff KR. Platelet-rich plasma: growth factor enhancement for bone grafts. Oral Surg Oral Med Oral Pathol Oral Raiol Endod. 1998;85:638-46.   DOI   ScienceOn
9 Wrotniak M, Bielecki T, Gazdzik TS. Current opinion about using the platelet-rich gel in orthopaedics and trauma surgery. Orthop Traumatol Rehabil. 2007;9:227-38.
10 Dallari D, Savarino L, Stagni C, et al. Enhanced tibial osteotomy healing with use of bone graft s supplemented with platelet gel or platelet gel and bone marrow stromal cells. J Bone Joint Surg. 2007;89:2413-20.   DOI   ScienceOn
11 Kitoh H, Kitakoji T, Tsuchiya H, et al. Transplantation of marrow- derived mesenchymal stem cells and platelet-rich plasma during distraction osteogenesis - a preliminary result of three cases. Bone. 2004;35:892-8.   DOI   ScienceOn
12 Delloye C, Cnockaert N, Cornu O. Bone substituetes in 2003: an overview. Acta Orthop Belg. 2003;69:1-8.
13 Giannoudis PV, Dinopoulos H, Tsiridis E. Bone substitutes: an update. Injury. 2005;36 Suppl:20-7.
14 Greenwald AS, Boden SD, Goldberg VM, Khan Y, Laurencin CT, Rosier RN. Bone-graft substitutes: facts, fictions, and applications. J Bone Joint Surg. 2001;83:98-103.   DOI
15 Bauer TW, Smith ST. Bioactive materials in orthopaedic surgery: overview and regulatory considerations. Clin Orthop Relat Res. 2002;395:11-22.   DOI
16 Betz RR. Limitations of autograft and allograft : new synthetic solutions. Orthopedics. 2002;25 Suppl 5: 561-70.
17 Bostman O, Pihlajamaki H. Clinical biocompatibility of biodegrad able orthopaedic implants for internal fixation: a review. Bio materials. 2000;21:2615-21.
18 Bauer TW, Muschler GF. Bone graft materials. An overview of the basic science. Clin Orthop Relat Res. 2000;371:10-27.   DOI